The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab.
Thomas Crosby
No relevant relationships to disclose
Chris Hurt
No relevant relationships to disclose
Stephen Falk
No relevant relationships to disclose
Simon Gollins
No relevant relationships to disclose
Somnath Mukherjee
No relevant relationships to disclose
John Staffurth
No relevant relationships to disclose
Ruby Ray
No relevant relationships to disclose
John A. Bridgewater
No relevant relationships to disclose
Ian Geh
No relevant relationships to disclose
David Cunningham
Research Funding - AstraZeneca; Merck; Roche
Tim Maughan
Research Funding - Merck Serono
Gareth Griffiths
No relevant relationships to disclose